| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5655034 | Diabetes & Metabolism | 2017 | 6 Pages |
Abstract
GLP1a treatment in a real-world setting may confer additional mortality benefit in patients with T2DM irrespective of their baseline CVD risk, age or baseline glycated haemoglobin and was sustained over the observation period.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
K.A. Toulis, W. Hanif, P. Saravanan, B.H. Willis, T. Marshall, B. Kumarendran, K. Gokhale, S. Ghosh, K.K. Cheng, P. Narendran, G.N. Thomas, K. Nirantharakumar,